Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 27, 2008. The report details a specific corporate action regarding the company's share buyback program authorized by shareholders at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share repurchases.
- Shares Purchased: 2,510,000 Ordinary shares of 25 pence each.
- Purchase Date: May 27, 2008.
- Purchase Price: 1,107.60 pence per share.
- Treasury Shares Held: 484,194,158 shares (representing 9.06% of total voting rights).
- Shares in Issue: 5,346,195,996 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of the company's share capital through the cancellation of 2,510,000 shares. Consequently, the number of shares held in Treasury increased to 484,194,158. The filing does not provide comparative financial data against prior periods.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total cost of the buyback transaction (2,510,000 shares at 1,107.60 pence).
- Confirm the updated total voting rights denominator (5,346,195,996 shares) for disclosure threshold calculations.
- Review the impact of the 9.06% Treasury share holding on future earnings per share (EPS) metrics.
- Check subsequent filings for the status of the remaining authorized buyback program.